Education and Experience
- University of Massachusetts Medical Center (Worcester MA)/ (1998)
- The Johns Hopkins Hospital (Baltimore MD)/ Internal Medicine (2001)
- The Johns Hopkins Hospital (Baltimore MD)/ Senior Clinical Fellow (2005)
- The Johns Hopkins Hospital (Baltimore MD)/ Oncology (2003)
- Medical Oncology, American Board of Internal Medicine (2009)
- Internal Medicine, American Board of Internal Medicine (2005)
- Sidney Kimmel Comprehensive Cancer Center
July 2003 Scholarship to attend week long ASCO/AACR Workshop. Methods in Clinical Cancer Research, an intensive workshop in the essentials of effective clinical trial design for clinical fellows and junior faculty clinical researchers in all subspecialties, including radiation and surgical oncology. Vail, Colorado.
July 2007 Scholarship to attend Communication Skills Training Course for Medical Oncology Faculty, Onco-teach. Principal Investigator: Dr. Anthony Bach from University of Washington School of Medicine. Two separate week long courses geared towards improving teaching skills for physician-patient communication and delivering bad news.
August 2010 Leadership Program for Women Faculty: Cohort program made up of 9 monthly half day sessions from Oct-June 2011. One of 30 women accepted into the program which is led by School of Medicine office of women in science and medicine (OWISM) and office of faculty development (OFD) and office of talent management and organization development (TMOD) at Johns Hopkins, Baltimore, Maryland.
August 2010 Abstract Reviewer and Moderator for MDS session at annual ASH symposium
December 2010 Myelodysplastic Syndromes 52nd Annual Meeting of the American Society of Hematology Orange County Convention Center, Orlando, Florida.
May 2011 NCCN Acute Lymphoblastic Leukemia Panel, Representative from Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Panel Member.
August 2011 Coordinating Reviewer for MDS abstracts and
Abstract Reviewer and Moderator for MDS session at annual ASH symposium,
December 2011 Myelodysplastic Syndromes 53nd Annual Meeting of the American Society of Hematology San Diego Convention Center, San Diego, California.
- Acute Lymphoblastic Leukemia
- Acute Myeloid Leukemia
- Chronic Lymphoblastic Leukemia
- Chronic Myeloid Leukemia
- General Internal Medicine
- Hematologic Malignancies
- Myelodysplastic Syndrome
- Myeloproliferative Disorders
School of Professional Studies in Business and Education
Graduate Division of Business and Management
Johns Hopkins University Baltimore, Maryland
Fenton H, Carlile B, Montgomery EA, Carraway HE, Herman J, Sahin F, Su GH, Argani P. LKB1 protein expression in human breast cancer. Appl Immunohistochem Mol Morphol 2006; 14:146-153.
Gore SD, Baylin S, Sugar E, Carraway H, Miller CB, Carducci M, Grever M, Galm O, Dauses T, Karp JE, Rudek MA, Zhao M, Smith BD, Manning J, Jiemjit A, Dover G, Mays A, Zwiebel J, Murgo A, Weng LJ, Herman JG. Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. Cancer Res 2006; 66:6361-6369.
Brandes JC, Carraway H, Herman JG. Optimal primer design using the novel primer design program: MSP primer provides accurate methylation analysis of the ATM promoter. Oncogene 2007; 26:6229-6237.
Karp JE, Ricklis RM, Balakrishnan K, Briel J, Greer J, Gore SD, Smith BD, McDevitt MA, Carraway H, Levis MJ, Gandhi V. A phase I clinical-laboratory study of clofarabine followed by cyclophosphamide for adults with refractory acute leukemias. Blood 2007; 110:1762-1769.
Abukhdeir AM, Vitolo MI, Argani P, De Marzo AM, Karakas B, Konishi H, Gustin, JP, Lauring J, Garay JP, Pendleton C, Konishi Y, Blair BG, Brenner K., Garrett-Mayer E, Carraway H, Bachman KE, Park BH. Tamoxifen stimulated growth of breast cancer due to p21 loss. Proc Natl Acad Sci 2008; 105:288-293.
Swinnen LJ, Rankin C, Carraway H, Albain KS, Townsend JJ, Budd GT, Kish JA, Rivkin SE, Blumenthal DT. A phase II study of cisplatin preceded by a 12-h continuous infusion of concurrent hydroxyurea and cytosine arabinoside (Ara-C) for adult patients with malignant gliomas (Southwest Oncology Group S9149). J Neurooncol 2008; 86:353-358.
Jiemjit A, Fandy TE, Carraway H, Bailey KA, Baylin S, Herman JG, Gore SD. p21(WAF1/CIP1) induction by 5-azacytosine nucleosides requires DNA damage. Oncogene 2008; 27:3615-3623.
Suzuki H, Toyota M, Carraway H, Gabrielson E, Ohmura T, Fujikane T, Nishikawa N, Sogabe Y, Nojima M, Sonoda T, Mori M, Hirata K, Imai K, Shinomura Y, Baylin SB, and Tokino T. Frequent epigenetic inactivation of Wnt antagonist genes in breast cancer. Br J Cancer 2008; 98:1147-1156.
Carraway HE, Wang S, Blackford A, Guo M, Powers P, Jeter S, Davidson NE, Argani P, Terrell K, Herman JG, Lange JR. Promoter hypermethylation in sentinel lymph nodes as a marker for breast cancer recurrence. Breast Cancer Res Treat 2009; 114:315-25. Epub 2008, Apr 11.
Guo M, Ren J, Brock MV, Herman JG, Carraway H. Promoter hypermethylation of HIN-1 in the progression to esophageal squamous cancer. Epigenetics 2008; 3:1-7.
Bailey V, Easwaran H, Zhang Y, Griffiths E, Belinsky S, Herman J, Baylin S, Carraway H*, Wang T. MS-qFRET: A quantum dot-based method for analysis of DNA methylation. Genome Res 2009; 19:1455-61.(*co-corresponding author)
Fandy TE, Herman JG, Kerns P, Jiemjit A, Sugar EA, Choi S, Yang AS, Aucott T, Dauses T, Odchimar-Reissig R, Licht J, McConnell J, Nasrallah C, Kim MKH, Zhang W, Sun Y, Murgo A, Espinoza-Delgado I, Oteiza K, Owoeye I, Silverman LR, Gore S, Carraway HE. Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies. Blood (Epub: Jun 22, 2009).
Figueroa M, Skrabanek L, Li Y, Jiemjit A, Fandy T, Paietta E, Tallman M, Greally J, Carraway H, Licht J, Gore S, Melnick A. MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation. Blood (Epub: Aug 3, 2009).
Ye Y, McDevitt MA, Guo M, Galm O, Karp JE, Gore SD, Maciejewski JP, Kowalski J, Tsai H, Gondek L, Wang X, Smith BD, Hooker C, Carraway H, Herman JG. Progressive chromatin repression and promoter methylation of ?-catenin correlates with AML transformation in patients with and without 5q deletions. Cancer Research (Accepted, Sept 2009).
Griffiths EA, Burns K, Hooker C, McDevitt M, Karp JE, Herman JG, Carraway HE. Acute myeloid leukemia is characterized by Wnt pathway inhibitor promoter methylation. Hematologica (submitted, Oct 2009).
Griffiths EA, Hooker C, McDevitt M, Karp JE, Herman JG, Carraway HE. Differences in promoter methylation of tumor suppressor genes in cytogenetically normal and abnormal acute myeloid leukemia. Clin Cancer Res (submitted, June 2009).
Vesuna F, Lisok A, Kimble J, Domek J, Kato Y, Artemov D, Carraway H, van Diest P, Raman V. Twist regulates estrogen receptor expression in breast cancer. JNCI (submitted, May 2009).
Bailey V, Keeley B, Zhang Y, Ho Y, Easwaran H, Brock M, Pelosky K, Carraway H, Baylin S, Herman J, Wang T. Enzymatic incorporation of multiple dyes for increased sensitivity in QD_FRET sensing for DNA methylation detection. Angenwandte Chemie (submitted, Sept 2009).
- Myelodysplastic Syndrome, Acute Leukemia